TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02444325

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group prenatal care
Description: Women will receive their prenatal care in a group rather than in the 1:1 traditional manner.
Study: NCT02486393

Intervention type: PROCEDURE
Intervention: Parotid surgery
Description: Surgery of the parotid gland tumours
Study: NCT01965600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06282999
Description: Tablet, 125 mg, TID, 3 days, 1 of 2 periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet, 0 mg, TID, 3 days, 1 of 2 periods

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LPS
Description: IV bolus, 4 ng/kg, 1 day, QD, 2 of 2 periods
Study: NCT04024436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Futibatinib
Description: Futibatinib 20mg once daily on a 28 day cycle
Study: NCT01406977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPS804
Study: NCT04024436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Futibatinib
Description: Futibatinib 20mg once daily on a 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Futibatinib plus Fulvestrant
Description: Futibatinib 20mg once daily and 500 mg fulvestrant administered intramuscularly (IM) on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond on a 28-day cycle.
Study: NCT04352023

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia
Description: Intravenous patient-controlled analgesia Patient-controlled epidural analgesia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia
Description: Intravenous patient-controlled analgesia Patient-controlled epidural analgesia
Study: NCT04342117

Intervention type: DRUG
Intervention: duvelisib
Description: 25 mg BID, 15 mg BID

Intervention type: DRUG
Intervention: PI3K inhibitor
Description: FDA approved PI3K inhibitors
Study: NCT01737216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid plus EP/TP
Description: Drug:EP/TP+Zoledronic acid EP(VP-16 100mg/m2 d1-3;DDP 60-75mg/m2 d1) every 4 weeks, for 4-6 cycles TP(PTX 135-175mg/m2 d1;DDP 60-75mg/m2 d1) every 3 weeks, for 4-6 cycles Zoledronic acid 4mg d1 every 3 months until bone metastasis, 4mg d1 every 1 month until progression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EP/TP
Description: Drug:EP/TP EP(VP-16 100mg/m2 d1-3;DDP 60-75mg/m2 d1) every 4 weeks, for 4-6 cycles TP(PTX 135-175mg/m2 d1;DDP 60-75mg/m2 d1) every 3 weeks, for 4-6 cycles
Study: NCT02776059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care + pegfiltrastim
Description: prednisolone or pentoxifyline orally for 28 days + pegfilgrastim (Neulasta®) 6 mg in 0.6 mL SQ

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Oral prednisolone or pentoxifyline for 28 days only
Study: NCT00976833

Intervention type: OTHER
Group type: OTHER
Intervention: Standardized Rehabilitation
Description: 3 component Rehabilitation approach, Passive Range of Motion, Physical Therapy and Progressive Resistance Training
Study: NCT02312726

Intervention type: PROCEDURE
Intervention: Postplacental IUD insertion
Description: Postplacental IUD insertion using the standardized ring forceps technique (Speroff and Mishell 2008) under ultrasound guidance, within 10-30 minutes of vaginal delivery.

Intervention type: PROCEDURE
Intervention: Postplacental IUD insertion
Description: Postplacental IUD insertion using the standardized ring forceps technique (Speroff and Mishell 2008) under ultrasound guidance, within 10-30 minutes of vaginal delivery.
Study: NCT01965600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06282999
Description: Tablet, 500 mg, BID, 3 days, 1 of 2 periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet, 0 mg, BID, 3 days, 1 of 2 periods
Study: NCT01435291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advagraf Capsule
Description: Other Names:~* FK506E~* MR4~* tacrolimus modified/prolonged release Drug: MPA Solution for infusion and per os Other Name: Mycophenolate Mofetil or Mycophenolic Acid Drug: Basiliximab IV infusion Other Name: Simulect Drug: Corticosteroids per os Other Name: Methylprednisolone or equivalent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf Capsule
Description: Other Names:~* FK506E~* MR4~* tacrolimus Drug: MPA Solution for infusion and per os Other Name: Mycophenolate Mofetil or Mycophenolic Acid Drug: Basiliximab IV infusion Other Name: Simulect Drug: Corticosteroids per os Other Name: Methylprednisolone or equivalent
Study: NCT01223144

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Iowa Gambling Task and Ekman facial recognition test
Description: Iowa Gambling Task: mean number of cards chosen from decks with low (A+B) and high gain (C+D).~Ekman facial recognition test: mean number of faces correctly recognized (60 images with 6 different expressions: happiness, sadness, fear, surprise, disgust and anger).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Iowa Gambling Task and Ekman facial recognition test
Description: Iowa Gambling Task: mean number of cards chosen from decks with low (A+B) and high gain (C+D).~Ekman facial recognition test: mean number of faces correctly recognized (60 images with 6 different expressions: happiness, sadness, fear, surprise, disgust and anger).
Study: NCT01529424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS apoC-III Rx
Description: Dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS apoC-III Rx
Description: Dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS apoC-III Rx
Description: Dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS apoC-III Rx
Description: Dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS apoC-III Rx
Description: Dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS apoC-III Rx
Description: Dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS apoC-III Rx
Description: Dose 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS apoC-III Rx
Description: Dose 3
Study: NCT04371406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine and Azithromycin
Description: Hydroxychloroquine sulfate (PLAQUENIL®), 200mg x 3 /d, for 10 days AND Azithromycin (ZITHROMAX®), 500mg on D1 and then 250mg/d for the next 4 days, in addition to standard of care

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Azinc
Description: Dietetary supplement, Azinc form and vitality®, 2 capsules per day, for 10 days, in addition to standard of care
Study: NCT03709225

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music-based meditation
Description: The program is designed to incorporate music-based meditation practices and music making activities (e.g., guitar, drums) to help promote relaxation during cancer treatment
Study: NCT00976833

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual Physical Therapy care
Study: NCT01166425

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium Carbonate
Description: Participants weighing ≥ 30 kg who are randomized to receive active lithium will begin treatment at 300 mg TID at visit 1 (total dose 900 mg). Participants weighing \< 30 kg who are randomized to receive active lithium will begin treatment at 300 mg BID the day after visit 1 (total dose 600 mg). Based on the participant's response and tolerability, the dose will be increased by 300mg three days after the baseline visit and at scheduled in-office visits to the maximum tolerated dose. One mid-week dose increase will be scheduled in addition to the weekly increases at the scheduled in-clinic visits. On day 3 (+/- 2 days), a dose increase of 300 mg may occur based on the results of a telephone call placed by the study investigator to the participant's parent/guardian. During the telephone call, the prescribing clinician will assess medication adherence, adverse events, and overall improvement since baseline.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants who are randomized to receive placebo during the Efficacy Phase will receive matching placebo capsules. Dosing will be titrated as described for active lithium.
Study: NCT02800525

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Picosecond laser
Description: Picosecond 532 and 1064 nm laser Treatment of facial pigmented lesions. The energy using depends on the endpoint of immediate whitening of the lesions. The wavelength using depends on the depth of lesions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Q-switched Nd:YAG laser
Description: Q-switched Nd-YAG 532 and 1064 nm laser. Treatment of facial pigmented lesions. The energy using depends on the endpoint of immediate whitening of the lesions. The wavelength using depends on the depth of lesion.
Study: NCT03477006

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Whole blood
Description: Low titer, group O, leukocyte reduced, platelet replete, cold stored whole blood
Study: NCT02306993

Intervention type: OTHER
Intervention: Healthy volunteers without SCT
Description: Subjects will undergo bone density evaluation via dual energy x-ray absorptiometry (DEXA) scanning. Subjects will provide a sample of for testing of bone turnover markers, complete blood count, and hemoglobin electrophoresis. Subjects will provide information about their dietary calcium intake and pain burden.

Intervention type: OTHER
Intervention: Healthy volunteers with SCT
Description: Subjects will undergo bone density evaluation via dual energy x-ray absorptiometry (DEXA) scanning. Subjects will provide a sample of for testing of bone turnover markers, complete blood count, and hemoglobin electrophoresis. Subjects will provide information about their dietary calcium intake and pain burden.
Study: NCT01802710

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological support

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Study: NCT02781610

Intervention type: DRUG
Group type: OTHER
Intervention: Standard of care IV antibiotic(s)
Description: IV antibiotics will be selected by the treating physician following standard of care. Duration of treatment is the assigned intervention.

Intervention type: DRUG
Group type: OTHER
Intervention: Standard of care IV antibiotic(s)
Description: IV antibiotics will be selected by the treating physician following standard of care. Duration of treatment is the assigned intervention.

Intervention type: DRUG
Group type: OTHER
Intervention: Standard of care IV antibiotic(s)
Description: IV antibiotics will be selected by the treating physician following standard of care. Duration of treatment is the assigned intervention.
Study: NCT02306993

Intervention type: OTHER
Intervention: Volunteers with SCD
Description: Subjects will undergo bone density evaluation via dual energy x-ray absorptiometry (DEXA) scanning. Subjects will provide a sample of for testing of bone turnover markers, complete blood count, and hemoglobin electrophoresis. Subjects will provide information about their dietary calcium intake and pain burden.
Study: NCT02735902

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K antagonist or direct oral anticoagulant treatment
Description: The Vitamin K antagonist or direct oral anticoagulant treatment will be administered to obtain an International Normalized Ratio between 2 and 3 as recommended if the treatment is AVK.~The Direct oral anticoagulant treatment : Apixaban 5 mg x2 or 2.5 mg X2, Edoxaban 30 ou 60 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin K antagonist or direct oral anticoagulant treatment
Description: The Vitamin K antagonist or direct oral anticoagulant treatment will be administered to obtain an International Normalized Ratio between 2 and 3 as recommended if the treatment is AVK.~The Direct oral anticoagulant treatment : Apixaban 5 mg x2 or 2.5 mg X2, Edoxaban 30 ou 60 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Daily dose is between 75 mg and 100 mg.~Allergic reactions to aspirin may be observed in rare cases. In case of suspicion of allergy, treatment with aspirin is stopped.
Study: NCT00897650

Intervention type: GENETIC
Intervention: DNA/RNA sequencing and expression levels
Description: Lung tumor tissue will be collected.

Intervention type: GENETIC
Intervention: Protein expression analysis
Description: Lung tumor tissue will be collected.

Intervention type: PROCEDURE
Intervention: Lung tumor biopsy
Description: Tissue will be collected by percutaneous fine needle aspiration, a percutaneous core biopsy, or during a medically indicated procedure during which lung tumor tissue will be removed
Study: NCT02781610

Intervention type: DRUG
Group type: OTHER
Intervention: Standard of care IV antibiotic(s)
Description: IV antibiotics will be selected by the treating physician following standard of care. Duration of treatment is the assigned intervention.
Study: NCT01600079

Intervention type: BIOLOGICAL
Intervention: ZOSTAVAX™
Description: ZOSTAVAX™ (Zoster Vaccine Live) administered in routine clinical conditions of use
Study: NCT00897650

Intervention type: PROCEDURE
Intervention: Blood sample
Description: Patients will be asked for a venous blood sample
Study: NCT03367195

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: 1 Omeprazole 20 mg capsules twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLBS2411
Description: 1 DLBS2411 caplet 250 mg, twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule of Omeprazole
Description: 1 placebo capsule of omeprazole, twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo caplet of DLBS2411
Description: 1 placebo caplet of DLBS2411, twice daily
Study: NCT02873793

Intervention type: GENETIC
Intervention: Extraction of total RNA from healthy and tumour tissues
Study: NCT04480658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bryophyllum pinnatum 50 %, tablets into capsules (verum: 2x2capsules/day)
Description: Bryophyllum is administered for 3 weeks. Bryophyllum is given in form of capsules, 350mg per capsule, 0-0-2-2/d: 2 capsules 30min. before supper,2 capsules before going to bed.~Other Names:~Bryophyllum pinnatum/Kalanchoe
Study: NCT00002913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC
Study: NCT03483415

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: Intravenous morphine infusion with PCA: Solution was concentration of 0.5 mg/mL. Loading dose of 1 mg, 0.5 mg of bolus dose and 20 min of locking time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Sulfate
Description: Intravenous morphine infusion with PCA: Solution was concentration of 0.5 mg/mL. Loading dose of 1 mg, 0.5 mg of bolus dose and 20 min of locking time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Ultrasound guided Long thoracic nerve blockage with 5 ml % 0.25 bupivacaine
Study: NCT02226887

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MESH
Description: 1. Pre-operative :~   It was made by barium enema protocol and transanal endoscopy to rule out anastomotic leaks or strictures contraindicating stoma closure .~2. Surgical technique:~   * Peristomal incision with electrocautery~  * Release the handle of ileum~  * Anastomosis made the with the segment everted sutured by simple manual end to end 3/0 or mechanical side to side (surgeon's election).~  * Return the ileum into the abdominal cavity and the fascial defect is repaired with continuous polydioxanone 1/0 suture respecting 4:1 measurement rule.~  * We add the mesh between the edges of the defect during fascia closure.~  * The skin is sutured purse string style.~3. Post-Op~   * Hospital discharge after verification of normal digestive transit.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NO MESH
Description: 1. Pre-operative :~   It was made by barium enema protocol and transanal endoscopy to rule out anastomotic leaks or strictures contraindicating stoma closure .~2. Surgical technique:~   * Peristomal incision with electrocautery~  * Release the handle of ileum~  * Anastomosis made the with the segment everted sutured by simple manual end to end 3/0 or mechanical side to side (surgeon's election).~  * Return the ileum into the abdominal cavity and the fascial defect is repaired with continuous polydioxanone 1/0 suture respecting 4:1 measurement rule.~  * The skin is sutured purse string style.~Post-Op~- Hospital discharge after verification of normal digestive transit
Study: NCT01965600

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LPS
Description: IV bolus, 4 ng/kg, 1 day, QD, 2 of 2 periods
Study: NCT02226887

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Post-operative Imaging
Description: Abdominal Tomography 1 year after ileostomy closure
Study: NCT02873793

Intervention type: GENETIC
Intervention: Extraction of total RNA from healthy and tumour tissues

Intervention type: GENETIC
Intervention: Extraction of total RNA from healthy and tumour tissues
Study: NCT03903302

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CS1-Sodium Valproate
Description: Single and multiple dose evaluation of CS1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CS1-Sodium Valproate
Description: Single and multiple dose evaluation of CS1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CS1-Sodium Valproate
Description: Single and multiple dose evaluation of CS1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CS1-Sodium Valproate
Description: Single and multiple dose evaluation of CS1
Study: NCT02226887

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Post-operative Imaging
Description: Abdominal Tomography 1 year after ileostomy closure

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pre-operative Imaging
Description: Contrast study is used to ensure the integrity of the distal anastomosis

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Pre-operative Imaging
Description: Contrast study is used to ensure the integrity of the distal anastomosis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Test and C-reactive protein at 4th day
Description: All patients undergo a Blood Test study of C-reactive protein on day 4 by protocol within the unit before discharge.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood Test and C-reactive protein at 4th day
Description: All patients undergo a Blood Test study of C-reactive protein on day 4 by protocol within the unit before discharge.
Study: NCT01630291

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrode device
Description: Lacrimal gland stimulation
Study: NCT02487862

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Stress Reduction Protocol
Description: Stress Reduction Protocol
Study: NCT00423449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Dose escalation study: vorinostat 300-500 mg capsules once daily for 7-14 days in continuous cycles of 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Dose escalation study: Gemcitabine 1000-1250 mg/m2 will be given for 2 days in each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum-based agent
Description: Cisplatin IV 75 mg/m2 will be given for 1 day in each 21 day cycle or carboplatin dosed according to renal function.
Study: NCT02699710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: Folic acid will be administered orally as tablet at a single dose of 5 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0853
Description: GDC-0853 will be administered orally as tablet or capsule at a dose of 200 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0853
Description: GDC-0853 will be administered orally as tablet or capsule at a dose of 200 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0853
Description: GDC-0853 will be administered orally as tablet or capsule at a dose of 200 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate will be administered orally as tablet at a single dose of 7.5 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Rabeprazole will be administered orally as tablet at a dose of 20 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Rabeprazole will be administered orally as tablet at a dose of 20 mg.
Study: NCT01153724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1744
Description: 10 mcg solution for oral inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1744
Description: 10 mcg solution for oral inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: 400 mg capsule
Study: NCT00374933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-myeloablative allogeneic stem cell transplant with prophylactic activated DLI
Description: Prophylactic delayed activated donor lymphocyte infusion (ADLI) after non-myeloablative conditioning and allogeneic peripheral blood cell stem cell transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prophylactic delayed ADLI
Description: Prophylactic ADLI after non-myeloablative conditioning and allogeneic peripheral blood cell stem cell transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prophylactic delayed activated donor lymphocyte infusion
Description: Prophylactic delayed activated donor lymphocyte infusion (ADLI) after non-myeloablative conditioning and allogeneic peripheral blood cell stem cell transplantation
Study: NCT01041820

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Children will be exposed to a 10-week exercise intervention
Study: NCT02628353

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 capsule of placebo product (100 mg carboxymetylcellulose) in one visit

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: phenolic compound
Description: 1 capsule of phenolic compound product (100mg phenolic compound + 100 mg carboxymetylcellulose) in one visit
Study: NCT02121249

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renaissance, Mazor Robotics Ltd, Caesare, Israel
Description: Renaissance (Mazor Robotics Ltd, Caesare, Israel) is the name of the robot

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: free hand technique
Description: No specific device is necessary in the free hand technique